Vestmark Advisory Solutions Inc. Boosts Stock Position in CVS Health Corporation $CVS

Vestmark Advisory Solutions Inc. boosted its stake in CVS Health Corporation (NYSE:CVS) by 48.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,370 shares of the pharmacy operator’s stock after purchasing an additional 2,091 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in CVS Health were worth $439,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in CVS Health by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 118,335,394 shares of the pharmacy operator’s stock worth $8,017,223,000 after acquiring an additional 969,027 shares during the last quarter. Dodge & Cox grew its holdings in shares of CVS Health by 4.8% during the first quarter. Dodge & Cox now owns 73,459,122 shares of the pharmacy operator’s stock worth $4,976,856,000 after purchasing an additional 3,353,223 shares in the last quarter. Invesco Ltd. raised its stake in CVS Health by 13.2% in the first quarter. Invesco Ltd. now owns 20,413,853 shares of the pharmacy operator’s stock valued at $1,383,039,000 after purchasing an additional 2,375,764 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in CVS Health by 14.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 15,309,289 shares of the pharmacy operator’s stock valued at $1,037,205,000 after purchasing an additional 1,942,886 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in CVS Health by 5.6% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 13,647,873 shares of the pharmacy operator’s stock worth $924,643,000 after buying an additional 728,924 shares in the last quarter. 80.66% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Anne A. Finucane sold 7,500 shares of CVS Health stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total value of $532,650.00. Following the sale, the director directly owned 22,156 shares in the company, valued at approximately $1,573,519.12. This trade represents a 25.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.22% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on CVS shares. Wolfe Research raised their price objective on shares of CVS Health from $80.00 to $85.00 and gave the company an “outperform” rating in a research report on Monday, September 22nd. The Goldman Sachs Group assumed coverage on CVS Health in a research report on Tuesday, October 14th. They set a “buy” rating and a $91.00 price target on the stock. UBS Group increased their price objective on CVS Health from $79.00 to $96.00 and gave the company a “buy” rating in a research report on Friday, October 24th. Robert W. Baird upgraded CVS Health from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $71.00 to $82.00 in a research report on Thursday, August 14th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of CVS Health in a research note on Wednesday, November 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $89.45.

CVS Health Stock Performance

NYSE:CVS opened at $79.73 on Wednesday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.62 and a current ratio of 0.83. CVS Health Corporation has a fifty-two week low of $43.56 and a fifty-two week high of $85.15. The business has a 50 day moving average price of $77.36 and a 200-day moving average price of $69.67. The firm has a market cap of $101.22 billion, a PE ratio of 209.83, a price-to-earnings-growth ratio of 0.87 and a beta of 0.60.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 earnings per share for the quarter, beating the consensus estimate of $1.36 by $0.24. The business had revenue of $102.87 billion during the quarter, compared to analysts’ expectations of $98.85 billion. CVS Health had a net margin of 0.12% and a return on equity of 11.45%. The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.09 EPS. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. Equities research analysts predict that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, November 3rd. Shareholders of record on Thursday, October 23rd were given a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, October 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 3.3%. CVS Health’s dividend payout ratio is presently 700.00%.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.